GSK's Physician Communications Shifts To Internal Experts, Remote Formats
This article was originally published in Scrip
New global approach means that GlaxoSmithKline no longer will pay outside health care professionals to speak on firms' behalf.
You may also be interested in...
Distribution limits for Cialis prompts concerns among 340B-eligible providers that Lilly will impose similar restrictions for additional products and that other manufacturers may follow suit.
Restricting orphan drug approvals could save the US billions of dollars, study from University of California’s Center for Health Policy and Economics suggests.
US Institute for Clinical and Economic Review lays out options ranging from the status quo (unrestricted pricing) to compulsory licensing and advanced market commitments in a new white paper.